Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis
Fabiola Atzeni,1 Antonio Carriero,2,3 Laura Boccassini,4 Salvatore D’Angelo2 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 2Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital of Pot...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-05-01
|
| Series: | ImmunoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/anti-il-17-agents-in-the-treatment-of-axial-spondyloarthritis-peer-reviewed-fulltext-article-ITT |
| _version_ | 1831539111188496384 |
|---|---|
| author | Atzeni F Carriero A Boccassini L D'Angelo S |
| author_facet | Atzeni F Carriero A Boccassini L D'Angelo S |
| author_sort | Atzeni F |
| collection | DOAJ |
| description | Fabiola Atzeni,1 Antonio Carriero,2,3 Laura Boccassini,4 Salvatore D’Angelo2 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 2Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; 3Translational and Clinical Medicine, Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy; 4Rheumatology Unit, Internal Medicine Department, ASST Fatebenefratelli-Sacco, University School of Medicine, Milan, ItalyCorrespondence: Fabiola AtzeniRheumatology Unit, Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria 1, Messina, 98100, ItalyTel +39 0902009Fax +39 0902000Email atzenifabiola@hotmail.comAbstract: Axial spondyloarthritis (axSpA) describes a group of chronic inflammatory rheumatic diseases primarily involving the axial skeleton. IL-17 is involved in the pathogenesis of numerous inflammatory diseases, including inflammatory arthritis. Until a few years ago, the only biological agents licensed for the treatment of axSpA and nr-axSpA were TNF inhibitors. However, as some patients did not respond to TNF inhibition or experienced secondary failure, the introduction of the first two IL-17 inhibitors (secukinumab [SEC] and ixekizumab [IXE]) has extended the treatment options, and there are now three others (bimekizumab, brodalumab and netakimab) in various stages of clinical development. The last ten years have seen the development of a number of therapeutic recommendations that aimed at improving the management of axSpA patients. The aim of this narrative review of the published literature concerning the role of IL-17 in the pathogenesis of SpA, and the role of IL-17 inhibitors in the treatment of axSpA, is to provide a comprehensive picture of the clinical efficacy and safety of the drugs themselves, and the treatment strategies recommended in the international guidelines.Keywords: spondyloarthritis, ankylosing spondylitis, non radiographic axial spondyloarthritis, axial spondyloarthritis, anti-TNF drugs, anti-IL17 drugs, interleukin 17 |
| first_indexed | 2024-12-16T23:34:30Z |
| format | Article |
| id | doaj.art-67e6d1566e2c4f7288564bc868ab3b6e |
| institution | Directory Open Access Journal |
| issn | 2253-1556 |
| language | English |
| last_indexed | 2024-12-16T23:34:30Z |
| publishDate | 2021-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ImmunoTargets and Therapy |
| spelling | doaj.art-67e6d1566e2c4f7288564bc868ab3b6e2022-12-21T22:11:46ZengDove Medical PressImmunoTargets and Therapy2253-15562021-05-01Volume 1014115364442Anti-IL-17 Agents in the Treatment of Axial SpondyloarthritisAtzeni FCarriero ABoccassini LD'Angelo SFabiola Atzeni,1 Antonio Carriero,2,3 Laura Boccassini,4 Salvatore D’Angelo2 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 2Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; 3Translational and Clinical Medicine, Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy; 4Rheumatology Unit, Internal Medicine Department, ASST Fatebenefratelli-Sacco, University School of Medicine, Milan, ItalyCorrespondence: Fabiola AtzeniRheumatology Unit, Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria 1, Messina, 98100, ItalyTel +39 0902009Fax +39 0902000Email atzenifabiola@hotmail.comAbstract: Axial spondyloarthritis (axSpA) describes a group of chronic inflammatory rheumatic diseases primarily involving the axial skeleton. IL-17 is involved in the pathogenesis of numerous inflammatory diseases, including inflammatory arthritis. Until a few years ago, the only biological agents licensed for the treatment of axSpA and nr-axSpA were TNF inhibitors. However, as some patients did not respond to TNF inhibition or experienced secondary failure, the introduction of the first two IL-17 inhibitors (secukinumab [SEC] and ixekizumab [IXE]) has extended the treatment options, and there are now three others (bimekizumab, brodalumab and netakimab) in various stages of clinical development. The last ten years have seen the development of a number of therapeutic recommendations that aimed at improving the management of axSpA patients. The aim of this narrative review of the published literature concerning the role of IL-17 in the pathogenesis of SpA, and the role of IL-17 inhibitors in the treatment of axSpA, is to provide a comprehensive picture of the clinical efficacy and safety of the drugs themselves, and the treatment strategies recommended in the international guidelines.Keywords: spondyloarthritis, ankylosing spondylitis, non radiographic axial spondyloarthritis, axial spondyloarthritis, anti-TNF drugs, anti-IL17 drugs, interleukin 17https://www.dovepress.com/anti-il-17-agents-in-the-treatment-of-axial-spondyloarthritis-peer-reviewed-fulltext-article-ITTspondyloarthritisankylosing spondylitisnon radiographic axial spondyloarthritisaxial spondyloarthritisanti-tnf drugsanti-il17 drugsinterleukin 17 |
| spellingShingle | Atzeni F Carriero A Boccassini L D'Angelo S Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis ImmunoTargets and Therapy spondyloarthritis ankylosing spondylitis non radiographic axial spondyloarthritis axial spondyloarthritis anti-tnf drugs anti-il17 drugs interleukin 17 |
| title | Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis |
| title_full | Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis |
| title_fullStr | Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis |
| title_full_unstemmed | Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis |
| title_short | Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis |
| title_sort | anti il 17 agents in the treatment of axial spondyloarthritis |
| topic | spondyloarthritis ankylosing spondylitis non radiographic axial spondyloarthritis axial spondyloarthritis anti-tnf drugs anti-il17 drugs interleukin 17 |
| url | https://www.dovepress.com/anti-il-17-agents-in-the-treatment-of-axial-spondyloarthritis-peer-reviewed-fulltext-article-ITT |
| work_keys_str_mv | AT atzenif antiil17agentsinthetreatmentofaxialspondyloarthritis AT carrieroa antiil17agentsinthetreatmentofaxialspondyloarthritis AT boccassinil antiil17agentsinthetreatmentofaxialspondyloarthritis AT dangelos antiil17agentsinthetreatmentofaxialspondyloarthritis |